Accueil / Communiqués / Computerized Systems for Managing Glucose Will Become Standard of Care in Hospitals, Anticipates Dr. Bruce Bode

Computerized Systems for Managing Glucose Will Become Standard of Care in Hospitals, Anticipates Dr. Bruce Bode

Tuesday, March 12th 2019 at 12:00pm UTC

A presentation at ATTD 2019 by renowned diabetologist and researcher,
Dr. Bruce Bode, showcased superior clinical and financial outcomes with
Glytec’s eGlycemic Management System
® versus
usual care across multiple studies.

WALTHAM, Mass.–(BUSINESS WIRE)– In conclusion to his plenary session at the 12th International
Conference on Advanced Technologies & Treatments for Diabetes (ATTD
2019), Dr. Bruce Bode delivered a call-to-action to an audience of his
peers, espousing they do what is necessary to normalize glucose for all
hospitalized patients (emphasis on ALL). He
stressed that rates of hypoglycemia remain unacceptably high and use of
sliding scale insulin continues to be prevalent despite abundant
evidence denouncing it as unsafe and lacking efficacy. “Patients deserve
better,” said Bode. With a clear focus on the solution to a decades-long
problem of poor glucose control in hospitals, Bode described in detail
the advantages of computerized decision support, highlighting data from
multiple studies
of Glytec’s FDA-cleared eGlycemic
Management System®
(eGMS®) that demonstrate
consistently superior outcomes versus usual care, including significant
reductions in hypoglycemia, 30-day readmissions and lengths of stay.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190312005141/en/

During his plenary session at the 12th International Conference on Advanced Technologies & Treatment ...

During his plenary session at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019), Dr. Bruce Bode stated the following regarding glucose management for hospitalized patients: « I fully envision that computerized systems will become the standard of care, because they serve the best interest of patients and providers, and they save money. » (Photo: Business Wire)

Representative Outcomes From Studies Mentioned:    

Outcome

                             

Usual Care

                             

Glytec eGMS®

                              Improvement
Average LOS Hospital-Wide1                               7.18 Days                               5.51 Days                               23.3% Decrease (1.67 Days)

Median LOS for DKA2

                              4.5 Days                               3.2 Days                               28.9% Decrease (1.3 Days)
Basal-Bolus Insulin Use3                               5%                               96%                               1,820% Increase (91% Absolute)
30-Day Readmission Rate for CABG4                               12.71%                               5.24%                               58.8% Decrease (7.47% Absolute)
POC Rate Hypoglycemia <40 mg/dL5                               0.41% BGs                               0.11% BGs                               73.2% Decrease (0.30% Absolute)

Bode further explained that concerns over glucose control go well beyond
patient safety, markedly impacting a hospital’s bottom line. He cited a
recent study by Florida Hospital System (now known as AdventHealth
Orlando): Financial
Implications of Poor Glycemic Management & Improvement Strategies for
Optimal Outcomes
. The study observed a $10,405 greater cost of
care (per stay) among insulin-managed patients who experienced severe
hypoglycemia when compared to patients whose blood sugar remained in the
normal range. Over a 12-month period from 2015 to 2016, the excess cost
amounted to $7.7 million.

“Value-based reimbursement and bundled payments necessitate a solution
to this problem,” said Bode. “This study exposed the extremely high cost
of poor glucose control in hospitalized patients. Things need to change.”

Bode mentioned four FDA-cleared systems that offer computerized glucose
management, but noted that Glytec’s eGMS® is the only one
capable of supporting diabetes therapies across both inpatient and
outpatient settings of care, and Glytec is the only company with an evidence
portfolio
validating the safety and efficacy of solutions for
intravenous insulin as well as subcutaneous basal-bolus insulin. Bode
also described a head-to-head
study
6 between Glytec’s Glucommander IV solution and
Monarch Medical Technologies’ EndoTool IV solution in which hypoglycemia
<70 mg/dL was 58% lower with Glucommander IV vs. EndoTool IV (9.6% vs.
23.0% patients), hypoglycemia <40 mg/dL was 100% lower (0.0% vs. 1.1%
patients) and duration on IV insulin was 45% lower (32.0 hours vs. 58.0
hours per patient).

“By normalizing, assessing and revising protocols and pathways for
hyperglycemic management, we can ultimately achieve the goal of
euglycemia without hypoglycemia,” said Bode, “and I fully envision that
computerized systems will become the standard of care, because they
serve the best interest of patients and providers, and they save money.”

________________________________
References:

1.

 

Safely
Converting From Sliding Scale to Basal Bolus Insulin Across an
Entire Medical Center via Implementation of the eGlycemic
Management System
. American Diabetes Association Scientific
Sessions, June 2017.

2.

Comparison
of Computer-Guided Versus Standard Insulin Infusion Regimens in
Patients with Diabetic Ketoacidosis
. American Association of
Clinical Endocrinologists Annual Scientific & Clinical Congress,
May 2016.

3.

Safely
Converting an Entire Academic Medical Center From Sliding Scale to
Basal Bolus Insulin via Implementation of the eGlycemic Management
System
. Journal of Diabetes Science and Technology, January
2018.

4.

Does
Glycemic Control Using eGMS Reduce Readmission Rates for
Hospitalized Patients Undergoing CABG?
Annual Diabetes
Technology Meeting, November 2016.

5.

Evaluating
the Impact of eGMS® Glucommander™ on Length of Stay,
Hypoglycemia and Glucose Control in a Regional Medical Center
.
Annual Diabetes Technology Meeting, November 2018.

6.

A
Comparison of Glycemic Outcomes for Two Computerized Insulin
Infusion Algorithms in CV Surgery Patients
. American Diabetes
Association Scientific Sessions, June 2016.

About Glytec

Glytec is the pioneer of personalized digital therapeutics, enabling
best practices for insulin optimization across the continuum of care.
The company’s patented and FDA-cleared software-as-a-medical-device
solutions improve the safety and health of people with diabetes in the
hospital and at home. Glytec combines evidence-based decision support
technologies with expert clinical services to make insulin a more
effective medication option for the millions unable to achieve their
treatment goals, leading to reductions in A1C, hypoglycemia and other
complications as well as avoidable ED visits, hospitalizations,
readmissions and drug waste. The company has offices in Waltham,
Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.

Contacts

Glytec
Joy Efron, 864-263-4160
Vice President Marketing
jefron@glytecsystems.com

Source: Glytec


Voir aussi

Innovations in Artificial Intelligence, Blockchain, Quantum Computing, Robots, and Catalysts, 2019 Study – ResearchAndMarkets.com

Friday, March 22nd 2019 at 3:01pm UTC DUBLIN–(BUSINESS WIRE)– The « Innovations in Artificial Intelligence, Blockchain, …